Micro-Costing Analysis of Thyroid Radiofrequency Ablation Compared with Hemithyroidectomy in Outpatient and Inpatient Settings [0.03%]
门诊和住院患者甲状腺射频消融与半甲状腺切除术的微成本分析
Harrison Gao,David Forner,Ben B Levy et al.
Harrison Gao et al.
Background: Thyroid radiofrequency ablation (RFA) is a minimally invasive treatment for thyroid nodules. However, the health system costs of thyroid RFA are not well defined in the current literature. As its use expands, ...
The Treatment of Advanced Thyroid Cancer Using Pemetrexed Monotherapy or with Platinum-Based Chemotherapy [0.03%]
单用培美曲塞或联合以铂为基础的化疗治疗甲状腺癌的效果研究
Laura Boucai,Rodrigo Fano,Eric J Sherman et al.
Laura Boucai et al.
Background: Mortality from thyroid cancer is driven by advanced forms of the disease. While second-line therapies have been approved and recognized in thyroid cancer guidelines, development of toxicity and resistance requ...
Marta Pérez-López,Petros Perros
Marta Pérez-López
Background: Graves' orbitopathy (GO) affects approximately 0.1% of the population. GO in anophthalmic patients is extremely rare and may provide insights into the pathogenesis of this disease. ...
Shorter Versus Standard Antithyroid Drug Therapy in Graves' Disease with Lower Baseline Thyrotropin Receptor Antibody (TRAb) Levels: Relapse Outcomes from a Propensity-Weighted Analysis [0.03%]
基线甲状腺刺激抗体水平较低的Graves病患者短程与常规抗甲状腺药物治疗复发结局的倾向加权分析
Salman Razvi,Mia Holley,Hannah Wheeler et al.
Salman Razvi et al.
Background: The optimal duration of antithyroid drug (ATD) therapy in Graves' disease is uncertain. Although guidelines recommend 12-18 months, shorter courses may be sufficient in selected patients. We evaluated whether ...
Methimazole-Associated Neutropenia and Agranulocytosis in Pediatric Patients with Graves' Disease: A Chinese Cohort Study [0.03%]
中国Graves病患儿甲巯咪唑致中性粒细胞减少和粒细胞缺乏症的队列研究
Shi Tang,Fang Zhang,Wanhong Zhu et al.
Shi Tang et al.
Background: Graves' disease (GD) is rare in children, and methimazole (MMI) is recommended as the first-line therapy. However, data on MMI-associated neutropenia and agranulocytosis in pediatric patients remain limited. I...
Prevalence and Distribution of Goiter Among Commercially Insured, Working-Age Adults in the United States [0.03%]
美国商业保险覆盖的劳动年龄成人甲状腺肿的流行病学和分布状况
Joseph Tobias,Joseph Krongold,Kerim Kaylan et al.
Joseph Tobias et al.
Background: We report a cross-sectional analysis of prevalence and distribution of goiter among commercially insured adults ages 18-64 in the United States using the 2022-2023 Merative™ MarketScan® Commercial Claims and...
Sneak Peek of the 2026 American Thyroid Association Annual Meeting, November 4-7 in Philadelphia [0.03%]
2026年美国甲状腺协会年度会议预览（11月4日至7日在费城举行）
Michael W Yeh,Sara Ahmadi
Michael W Yeh
Loss of Thyroid Hormone Transporters MCT8 and OATP1C1 in Mouse Oligodendroglia Cells Results in a Delayed Oligodendrocyte Maturation and Myelination [0.03%]
小鼠少突胶质细胞中甲状腺激素转运蛋白MCT8和OATP1C1丢失导致少突胶质细胞成熟和髓鞘化延迟
Joshua-Joel Richter,Boyka Markova,Beyza Atalay et al.
Joshua-Joel Richter et al.
Background: Due to an impaired thyroid hormone (TH) transport across brain barriers, inactivation of the murine TH transporters Mct8/Oatp1c1 causes a profound TH deficiency of the CNS that greatly impacts neural developme...
Letter to the editor: When Guidelines Meet Reality: Implementing the 2025 ATA Recommendations for Differentiated Thyroid Cancer in Limited-Resource Settings [0.03%]
致编辑的信：当指南遇到现实：在资源有限的情况下实施2025年ATA关于分化型甲状腺癌的建议
Fabián Pitoia,Erika Abelleira,Anabella Smulever et al.
Fabián Pitoia et al.
Stimulating Thyrotropin Receptor Antibodies Enhance the Expression of Both Thyrotropin Receptors and Insulin-Like Growth Factor 1 Receptors in Fibroblasts [0.03%]
促甲状腺素受体抗体刺激可增强成纤维细胞中促甲状腺素受体和胰岛素样生长因子1受体的表达
Pingping Xiang,Mihaly Mezei,Rauf Latif et al.
Pingping Xiang et al.
Background: Thyrotropin (TSH) and insulin-like growth factor 1 (IGF-1) signals have been shown to be additive in their action on thyroid cells and fibroblasts, and this coordination emphasizes the role of TSH receptor (TS...